lung cancer
No description yet: the sentence for this tag has not been written. 16 records carry it: 16 people.
Related tags
16 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Alexis Cortot President · Intergroupe Francophone de Cancérologie Thoracique Lille pulmonologist and thoracic oncologist who presides over the IFCT, France's academic lung cancer trials group. | Non-small-cell lung cancer, Small-cell lung cancer | none | leadership, clinician-scientist, clinical trials | ||
Alfredo Addeo Head of Division, Oncology · Geneva University Hospitals (HUG) Thoracic oncologist who heads the Oncology Division at Geneva University Hospitals. | Non-small-cell lung cancer, Small-cell lung cancer, Mesothelioma | none | leadership, clinician-scientist, immunotherapy | ||
Caicun Zhou Professor of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University; President, IASLC (2025-2027) · Shanghai Pulmonary Hospital Principal investigator of HARMONi-2, the trial where ivonescimab beat pembrolizumab head-to-head, and of the first EGFR-TKI phase 3 in Chinese patients. | Non-small-cell lung cancer, Small-cell lung cancer | none | leadership, clinician-scientist | ||
David Planchard Board member (Conseil d'Administration) · Intergroupe Francophone de Cancérologie Thoracique Gustave Roussy thoracic oncologist on the IFCT board, widely published on BRAF- and EGFR-targeted therapy in lung cancer. | Non-small-cell lung cancer | none | clinician-scientist, targeted therapy | ||
Hidetoshi Hayashi Vice-President · Japanese Society of Medical Oncology Vice-President of JSMO and thoracic medical oncologist at Kindai University known for clinical trials of targeted therapies in lung cancer. | Non-small-cell lung cancer | none | leadership, clinician-scientist | ||
Jin Seok Ahn President (14th) · Korean Cancer Study Group Medical oncologist serving as 14th President of the Korean Cancer Study Group, Korea's main academic cooperative trials group. | Non-small-cell lung cancer | none | leadership, clinician-scientist, clinical trials | ||
Karen Kelly Chief Executive Officer · International Association for the Study of Lung Cancer Thoracic medical oncologist who serves as CEO of the International Association for the Study of Lung Cancer. | Non-small-cell lung cancer, Small-cell lung cancer, Mesothelioma | none | leadership, clinician-scientist | ||
Karim Vermaelen Chairperson, CRIG Steering Committee (2026-2028) · Ghent University Hospital / Cancer Research Institute Ghent Thoracic oncologist and tumour immunologist who chairs the Cancer Research Institute Ghent at Ghent University / UZ Gent. | Non-small-cell lung cancer, Mesothelioma | none | leadership, clinician-scientist, immunotherapy | ||
Luis Paz-Ares Head of the H12O-CNIO Lung Cancer Clinical Research Unit · Hospital Universitario 12 de Octubre Madrid medical oncologist who heads the joint 12 de Octubre-CNIO lung cancer clinical research unit and led the KEYNOTE-407 trial in squamous lung cancer. | Non-small-cell lung cancer, Small-cell lung cancer | none | clinician-scientist, immunotherapy | ||
Martin Schuler Deputy Director WTZ Essen · West German Cancer Center (WTZ), University Hospital Essen Medical oncologist and lung cancer trialist who is Deputy Director of the West German Cancer Center in Essen. | Non-small-cell lung cancer, Small-cell lung cancer | none | leadership, clinician-scientist | ||
Matthias Guckenberger Past-President · European Society for Radiotherapy and Oncology Zurich radiation oncologist and ESTRO Past-President, a leading voice on stereotactic radiotherapy for oligometastases. | Non-small-cell lung cancer | none | leadership, clinician-scientist, radiotherapy | ||
Nobuyuki Yamamoto Chairman · West Japan Oncology Group Lung cancer specialist at Wakayama Medical University who chairs the West Japan Oncology Group cooperative trials network. | Non-small-cell lung cancer, Small-cell lung cancer | none | leadership, clinician-scientist, clinical trials | ||
Shun Lu Professor; Director, Shanghai Lung Cancer Center, Shanghai Chest Hospital · Shanghai Chest Hospital A Shanghai lung cancer trialist who has led many Chinese PD-1 and EGFR-TKI phase 3 studies. | Non-small-cell lung cancer, Small-cell lung cancer | none | clinician-scientist, targeted therapy | ||
Suresh S. Ramalingam Executive Director · Winship Cancer Institute of Emory University Lung cancer medical oncologist who leads Winship Cancer Institute of Emory University and led the FLAURA trial of osimertinib. | Non-small-cell lung cancer, Small-cell lung cancer | none | leadership, clinician-scientist, targeted therapy | ||
Tony S. K. Mok Chairman, Department of Clinical Oncology; Li Shu Fan Professor of Clinical Oncology · Prince of Wales Hospital / Chinese University of Hong Kong Lung cancer pioneer whose IPASS trial established EGFR-targeted therapy as first-line treatment; chairs Clinical Oncology at CUHK. | Non-small-cell lung cancer | none | leadership, clinician-scientist, precision oncology | ||
Wen-Zhao Zhong Vice President and Party Standing Committee Member · Guangdong Provincial People's Hospital Thoracic surgeon-scientist and hospital Vice President who led the ADJUVANT/CTONG1104 trial establishing adjuvant EGFR-TKI therapy in resected lung cancer. | Non-small-cell lung cancer | none | clinician-scientist, leadership, thoracic surgery |